MedTrace Logo

Allergen Challenge Chamber Study With Single Dose Intranasal GSK1004723 Compared With Placebo

NCT00824356 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2009-06-22

No results posted yet for this study

Summary

This is a placebo-controlled, 3-period crossover study to assess the efficacy and safety of two single doses of an intranasal anti-histamine GSK1004723 compared with placebo in an allergen challenge chamber in male subjects with seasonal allergic

Conditions

  • Allergic Rhinitis

Interventions

DRUG

GSK1004723 (200mg)

Intranasal antihistamine.

OTHER

Placebo

Equivalent to GSK1004723 in presentation etc.

DRUG

GSK1004723 (1000mg)

Intranasal antihistamine.

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2008-08-31
Completion
2008-08-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00824356 on ClinicalTrials.gov